Tuesday, June 12, 2012

Igenica Raises $33M For Cancer Antibodies

Burlingame-based Igenica, a developer of biopharmaceuticals focused on the cancer market, has raised $33M in a Series C funding round. The round was led by Third Rock Ventures, and also included The Column Group, Orbimed Advisors and 5AM Ventures. According to the company, the funding brings its total raised to $55M. The funding will go towards clinical trials of its products, which are antibody-based cancer medicines. More information »